Gilead Sciences (GILD) Amortizatization of Intangibles (2009 - 2026)
Gilead Sciences (GILD) reported Amortizatization of Intangibles of $596.0 million for Q1 2026, down 0.5% on a YoY basis from $599.0 million in Q1 2025, and little changed quarter-over-quarter from $597.0 million in Q4 2025.
Gilead Sciences (GILD) Amortizatization of Intangibles (2009 - 2026) Analysis & Trends
Gilead Sciences has reported Amortizatization of Intangibles for 18 years, with the latest figure at $596.0 million in Q1 2026.
- For the quarter ending Q1 2026, Amortizatization of Intangibles fell 0.5% year-over-year to $596.0 million; the trailing twelve-month figure through Mar 2026 stood at $2.4 billion (changed 0.08% YoY), and the FY2025 full-year result was $2.4 billion, changed 0.17% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $596.0 million, roughly flat from $597.0 million in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $599.0 million in Q1 2025, with the low at $445.0 million in Q1 2022.
- Historically, Amortizatization of Intangibles has averaged $558.3 million across 5 years, with a median of $596.0 million in 2024.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles soared 34.38% — and 2026, when it dropped 0.5%.
- Gilead Sciences' Amortizatization of Intangibles stood at $445.0 million in 2022, then jumped by 34.16% to $597.0 million in 2023, then increased by 0.17% to $598.0 million in 2024, then dropped by 0.17% to $597.0 million in 2025, then slipped by 0.17% to $596.0 million in 2026.
- The last three Amortizatization of Intangibles figures came in at $596.0 million (Q1 2026), $597.0 million (Q4 2025), and $596.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | - |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 1.70 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 931.00 Mn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 596.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | - |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 596.00 Mn |
| Mar 31, 2026 | 596.00 Mn |
| Dec 31, 2025 | 597.00 Mn |
| Dec 31, 2025 | 597.00 Mn |
| Sep 30, 2025 | 596.00 Mn |
| Sep 30, 2025 | 596.00 Mn |
| Jun 30, 2025 | 598.00 Mn |
| Jun 30, 2025 | 598.00 Mn |
| Mar 31, 2025 | 599.00 Mn |
| Mar 31, 2025 | 599.00 Mn |
| Dec 31, 2024 | 598.00 Mn |
| Dec 31, 2024 | 598.00 Mn |
| Sep 30, 2024 | 596.00 Mn |
| Sep 30, 2024 | 596.00 Mn |
| Jun 30, 2024 | 596.00 Mn |
| Jun 30, 2024 | 596.00 Mn |
| Mar 31, 2024 | 596.00 Mn |
| Mar 31, 2024 | 596.00 Mn |
| Dec 31, 2023 | 597.00 Mn |
| Dec 31, 2023 | 597.00 Mn |